ArticleAnnals of gastroenterological surgery2026
To Evaluate Whether Pretreatment CA19-9 and DUPAN-2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Pancreatic cancer (PC) remains one of the most lethal malignancies, with early recurrence severely affecting prognosis even after curative resection. While neoadjuvant treatments (NAT), such as gemcitabine plus S-1 (NAT-GS), have improved outcomes, predicting their effectiveness and optimizing patient selection remain challenging. This study aimed to investigate whether pretreatment CA19-9 and DUPAN-2 levels can serve as predictive markers to guide the choice between NAT and upfront surgery in pancreatic cancer. Methods: We retrospectively analyzed 190 patients with PC (67 with NAT-GS and 123 with upfront surgery). Patients were stratified into three groups based on their pre-NAT CA19-9/DUPAN-2 levels: both within the reference range, one exceeding, or both exceeding. The 12 month recurrence-free survival (12MRFS) rates were assessed using the Kaplan-Meier method, with log-rank and other appropriate statistical tests for comparison. Results: NAT-GS was significantly more effective only in patients with one tumor marker above the reference range, comparing those who achieved 12 month MRFS with those who did not. In the Kaplan-Meier curve, among patients with only one elevated tumor marker, the NAT-GS group showed a significantly better 12MRFS ratio than the upfront surgery group (78.6% vs. 51.2%, Conclusion: The combination of pre-NAT CA19-9 and DUPAN-2 levels may serve as a useful criterion for selecting between upfront surgery, NAT-GS, or more intensive chemotherapy. This suggests the possibility of a tailored approach, in which a combination of tumor markers would determine whether to opt for upfront surgery, NAT-GS, or more intensive chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.